Sex-based discrimination in medicine costs lives | Letters

A review of global research highlighted that women are less likely than men to be offered active treatment for identical health conditions, a disparity that directly costs lives. The letter’s author, head of pharmacovigilance at a clinical‑trials technology firm, cites a British Heart Foundation‑funded study showing women receive fewer recommended interventions after a heart attack, and a 2018 analysis estimating that more than 8,000 female deaths over a decade could have been avoided if women had received the same standard of care as men. The problem is rooted in long‑standing under‑representation of women in clinical trials, originally driven by policies excluding potentially pregnant participants and compounded by practical barriers such as women’s dual responsibilities at home and work, which make trial participation difficult.

The consequences of this under‑representation are stark: women experience 50‑70 % more drug side‑effects than men because trial data rarely reflect their physiological realities. The letters argue that without adequate female enrolment, medication safety and efficacy remain skewed, perpetuating a cycle where women receive less treatment across a spectrum of conditions—from kidney and heart disease to liver disorders—rather than only in traditionally “women’s” specialties. Authors call for mandatory education in sex‑ and gender‑sensitive medicine for all healthcare professionals, beginning in schools with stronger sex‑and‑health curricula, to dismantle entrenched biases. They see the renewed women’s health strategy and England’s 10‑year health plan as pivotal moments to institutionalise these changes and ensure women obtain equal access to timely diagnosis, appropriate investigations, and effective care.

Personal testimonies underscore the broader impact. One contributor recounts enduring severe pelvic pain until a Guardian article led her to a female gynaecologist who recommended physiotherapy tailored to women’s health—a treatment she had not previously encountered. Another writer praises increased discussion of endometriosis but warns that many women’s health issues remain neglected. Both stress that the solution lies not in preferential treatment but in equitable, evidence‑based care, which requires expanding trial inclusion, improving practitioner education, and making specialised therapies widely available. The letters conclude that without these systemic reforms, sex‑based discrimination will continue to jeopardise women’s health outcomes.

⚡ Effects Interpreter